Different metabolic and anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: Results from the "NEVIRAPINE COMPANION" cohort

Purpose of the study

To assess metabolic, anthropometric and cardiovascular risk profile of a cohort undergoing stable nevirapine therapy associated with TDF+FTC (TVD), AZT+3TC (CBV) or ABC+3TC (KVX).

Methods

Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic undergoing nevirapine therapy for >6 months associated with TVD, CBV or KVX.

Summary of results

244 patients were included. Table 1.

Table 1

Rho of Spearman did not find any correlation between NVP exposure and the surrogate toxicity end-points (all: p = ns).

Conclusion

KVX arm displayed a greater pro-atherogenic risk profile notwithstanding lower BMI in respect to CBV and TVD. This non-randomised cohort cannot discriminate if patients with a higher underlying risk of cardiovascular disease might be initially placed on KVX or if KVX associated with NVP per se, had a poorer metabolic profile compared with the TVD and CBV arms. Careful assessment of metabolic parameters should be evaluated in people undergoing the association KVX+NEV even beyond the initial 6 months of therapy and appropriate lipid-lowering therapy started if needed.